Trends of prevalence of primary HIV drug resistance in Germany

Journal of Antimicrobial Chemotherapy

Volumn 60, Issue 4, 2007, Pages 843-848

  Sagir, Abdurrahman ^a   Oette, Mark ^a   Kaiser, Rolf ^b   Däumer, Martin ^b   Fätkenheuer, Gerd ^b   Rockstroh, Jürgen Kurt ^c   Knechten, Heribert ^d   Schmutz, Günther ^e   Hower, Martin ^f   Emmelkamp, Jetske ^a   Pfister, Herbert ^b   Häussinger, Dieter ^a  

^a UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

^c UNIVERSITY OF BONN   (Germany)

^d Private Practice   (Germany)

^e Private Practice   (Germany)

^f KLINIKUM DORTMUND   (Germany)

Author keywords

Epidemiology; HAART; RESINA

Indexed keywords

ANTIRETROVIRUS AGENT; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; ASIAN; BLOOD TRANSFUSION; CAUCASIAN; CLINICAL PRACTICE; CONTROLLED STUDY; DISEASE TRANSMISSION; ETHNIC DIFFERENCE; FEMALE; GENOTYPE; GERMANY; HETEROSEXUALITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOMOSEXUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; NEGRO; PREVALENCE; RISK ASSESSMENT; RISK FACTOR; SEX RATIO; TREATMENT OUTCOME; VERTICAL TRANSMISSION;

DRUG RESISTANCE, VIRAL; ETHNIC GROUPS; FEMALE; GENOME, VIRAL; GENOTYPE; GERMANY; HIV; HIV INFECTIONS; HUMANS; MALE; PROSPECTIVE STUDIES; SEXUAL BEHAVIOR;

EID: 34548779666     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkm274     Document Type: Article

References (32)

1. Bartlett JA, DeMasi R, Quinn J et al. Overview of the effectiveness of triple combination therapy in antiretroviral-naive HIV-1 infected adults. AIDS 2001; 15: 1369-77.
2. Aleman S, Soderberg K, Visco-Comandini U et al. Drug resistance at low viraemia in HIV-1-infected patients with antiretroviral combination therapy. AIDS 2002; 16: 1039-44.
3. Balotta C, Berlusconi A, Pan A et al. Prevalence of transmitted nucleoside analogue-resistant HIV-1 strains and pre-existing mutations in pol reverse transcriptase and protease region: Outcome after treatment in recently infected individuals. Antivir Ther 2000; 5: 7-14.
4. Cozzi Lepri A, Sabin CA, Staszewski S et al. Resistance profiles in patients with viral rebound on potent antiretroviral therapy. J Infect Dis 2000; 181: 1143-7.
5. Richman DD, Morton SC, Wrin T et al. The prevalence of antiretroviral drug resistance in the United States. AIDS 2004; 18: 1393-401.
6. Boden D, Hurley A, Zhang L et al. HIV-1 drug resistance in newly infected individuals. JAMA 1999; 282: 1135-41.
7. Salomon H, Wainberg MA, Brenner B et al. Prevalence of HIV-1 resistant to antiretroviral drugs in 81 individuals newly infected by sexual contact or injecting drug use. Investigators of the Quebec Primary Infection Study. AIDS 2000; 14: F17-23.
8. Little SJ, Holte S, Routy JP et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 2002; 347: 385-94.
9. Yerly S, Rickenbach M, Popescu M et al. Drug resistance mutations in HIV-1-infected subjects during protease inhibitor-containing highly active antiretroviral therapy with nelfinavir or indinavir. Antivir Ther 2001; 6: 185-9.
10. Simon V, Vanderhoeven J, Hurley A et al. Evolving patterns of HIV-1 resistance to antiretroviral agents in newly infected individuals. AIDS 2002; 16: 1511-9.
11. Erice A, Mayers DL, Strike DG et al. Brief report: Primary infection with zidovudine-resistant human immunodeficiency virus type 1. N Engl J Med 1993; 328: 1163-5.
12. Veenstra J, Schuurman R, Comelissen M et al. Transmission of zidovudine-resistant human immunodeficiency virus type 1 variants following deliberate injection of blood from a patient with AIDS: characteristics and natural history of the virus. Clin Infect Dis 1995; 21: 556-60.
13. Oette M, Kaiser R, Daumer M et al. Primary HIV drug resistance and efficacy of first-line antiretroviral therapy guided by resistance testing. J Acquir Immune Defic Syndr 2006; 41: 573-81.
14. Violin M, Cozzi-Lepri A, Velleca R et al. Risk of failure in patients with 215 HIV-1 revertants starting their first thymidine analog-containing highly active antiretroviral therapy. AIDS 2004; 18: 227-35.
15. Grant RM, Hecht FM, Warmerdam M et al. Time trends in primary HIV-1 drug resistance among recently infected persons. JAMA 2002; 288: 239-41.
16. Beerenwinkel N, Schmidt B, Walter H et al. Diversity and complexity of HIV-1 drug resistance: A bioinformatics approach to predicting phenotype from genotype. Proc Natl Acad Sci USA 2002; 99: 8271-6.
17. Johnson VA, Brun-Vezinet F, Clotet B et al. Drug resistance mutations in HIV-1. Top HIV Med 2003; 11: 215-21.
18. Chaix ML, Descamps D, Harzc M et al. Stable prevalence of genotypic drug resistance mutations but increase in non-B virus among patients with primary HIV-1 infection in France. AIDS 2003; 17 2635-43.
19. Adje C, Cheingsong R, Roels TH et al. High prevalence of genotypic and phenotypic HIV-1 drug-resistant strains among patients receiving antiretroviral therapy in Abidjan, Cote d'Ivoire. J Acquir Immune Defic Syndr 2001; 26: 501-6.
20. Babic DZ, Zelnikar M, Seme K et al. Prevalence of antiretroviral drug resistance mutations and HIV-1 non-B subtypes in newly diagnosed drug-naive patients in Slovenia, 2000-2004. Virus Res 2006; 118 156-63.
21. Leigh Brown AJ, Frost SD, Mathews WC et al. Transmission fitness of drug-resistant human immunodeficiency virus and the prevalence of resistance in the antiretroviral-treated population. J Infect Dis 2003; 187: 683-6.
22. Ristig MB, Arens MQ, Kennedy M et al. Increasing prevalence of resistance mutations in antiretroviral-naive individuals with established HIV-1 infection from 1996-2001 in St. Louis. HIV Clin Trials 2002; 3: 155-60.
23. Wensing AM, van de Vijver DA, Angarano G et al. Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. J Infect Dis 2005; 192 958-66.
24. Cane P, Chrystie I, Dunn D et al. Time trends in primary resistance to HIV drugs in the United Kingdom: Multicentre observational study. BMJ 2005; 331: 1368.
25. Brenner B, Wainberg MA, Salomon H et al. Resistance to antiretroviral drugs in patients with primary HIV-1 infection. Investigators of the Quebec Primary Infection Study. Int J Antimicrob Agents 2000; 16: 429-34.
26. Fox J, Dustan S, McClure M et al. Transmitted drug-tesistant HIV-1 in primary HIV-1 infection; incidence, evolution and impact on response to antiretroviral therapy. HIV Med 2006; 7: 477-83.
27. Ammaranond P, Cunningham P, Oelrichs R et al. Rates of transmission of antiretroviral drug resistant stains of HIV-1. J Clin Virol 2003; 26: 153-61.
28. Booth CL, Garcia-Diaz AM, Youle MS et al. Prevalence and predictors of antiretroviral drug resistance in newly diagnosed HIV-1 infection. J Antimicrob Chemother 2007; 59: 517-24.
29. Weinstock HS, Zaidi I, Heneine W et al. The epidemiology of antiretroviral drug resistance among drug-naive HIV-1-infected persons in 10 US cities. J Infect Dis 2004; 189: 2174-80.
30. Miller V. HIV drug resistance: Overview of clinical data. J HIV Ther 2001; 6: 68-71.
31. Vandamme AM, Sonnerborg A, Ait-Khaled M et al. Updated European recommendations for the clinical use of HIV drug resistance testing. Antivir Ther 2004; 9: 829-48.
32. Sax PE, Islam R, Walensky RP et al. Should resistance testing be performed for treatment-naive HIV-infected patients? A cost-effectiveness analysis. Clin Infect Dis 2005; 41: 1316-23.